Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

BiOasis Technologies Inc V.BTI

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  BIOAF

biOasis Technologies Inc is a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier and into the brain tissue. Its focus is to address unmet medical needs with its proprietary Transcend Platform.
Price: $1.18 | Change: +$0.03 | %Change: +2.61%
Volume: 11,500 | Day High/Low: 1.19/1.18 | 52 Week High/Low: 1.50/0.75
View modes: 
0 stars

More evidence that BTI has a universally successful carrier

"This knockout mouse model of Hunter Syndrome (MPS II) showed that the Transcend fusion protein, MTfp-I2S (MTfp-Iduronate-2-sulfatase), was able to cross the blood-brain barrier, reached therapeutic...read more
5 stars

RE:RE:more details in the PR

there has to be a reason that we have not received the full data sets on all three studies. I don't believe the reason is that they are trying to hide anything as sir holler wrote earlier, especially...read more
4 stars

RE:more details in the PR

you really have to take a good hard look at what j.d has said all along in regards to deals and things really beginning to snowball with bioasis now more than ever. lovin coal makes another great...read more
3 stars

more details in the PR

just want to remind everyone that if you are filing an IND with the FDA or presenting your findings at a conference you are restricted from publishing all your research findings.  rate and reply
5 stars

Scarpa

I think a man of his standing in this field gave an appropriate and measured response.....The devil in the details will emerge.....I would like J.D and pmriders thoughts on the press release  rate and reply
4 stars

RE:RE:RE:RE:RE:RE:RE:RE:What Hunter Syndrome Could Be Worth:

agreed. we need more clarity from the company. however, their deal with harvard recently is encouraging as if the results were poor, why would harvard come on board?  rate and reply
1 star

RE:RE:RE:RE:RE:RE:What Hunter Syndrome Could Be Worth:

http://www.stockhouse.com/companies/bullboard/v.bti/bioasis-technologies-inc?postid=23983284 Sure below I will explain kayaker, but perhaps you missed the above post of mine. The $225M is really $15M...read more
3.5 stars

RE:RE:RE:RE:RE:RE:RE:What Hunter Syndrome Could Be Worth:

"but its been seeming that no matter how great our results are with herceptin....sirna....and now hunter syndrome we arent anywhere near the value of the other preclinical companies you listed." They...read more
5 stars

RE:RE:RE:RE:RE:RE:What Hunter Syndrome Could Be Worth:

Well our vector got 6.4 times more dosage across the bbb...so im hopefull that we get a deal now....but its been seeming that no matter how great our results are with herceptin....sirna....and now...read more
5 stars

RE:RE:RE:RE:RE:What Hunter Syndrome Could Be Worth:

mister regardless, no one pays even $4M for pre-clinical stage products, so you slipped a few digits. eunice, I (and most folks here) would say you are quite wrong on that.  Perhaps you can explain...read more
1 star

RE:RE:RE:RE:RE:What Hunter Syndrome Could Be Worth:

Eunice. i guess what i was trying to say is that im alot more confident now that its great news every time.we read something lately and i guess i am more sure now than hopefull. im still hoping fpr...read more
0 stars

RE:RE:RE:RE:What Hunter Syndrome Could Be Worth:

I don't read Hollers posts so shouldn't have said you were wrong. Perhaps the sales value lies between your and my estimates but likely far away from each.  rate and reply
5 stars

RE:RE:RE:What Hunter Syndrome Could Be Worth:

"no one pays even $4M for pre-clinical stage products" Armagen received US$15 million in upfront cash and equity investments alone for Hunter's Syndrome, in addition to the other payments and...read more
4.5 stars

RE:RE:RE:What Hunter Syndrome Could Be Worth:

Eunice..if you do read the board back for almost a year you will see that many people here assume and think that big money deals can and will come to this pre clinical company. Personally i never...read more
1 star

RE:RE:What Hunter Syndrome Could Be Worth:

mister regardless, no one pays even $4M for pre-clinical stage products, so you slipped a few digits. It is my understanding that since it has never entered a human body, or at least not in its...read more
4.5 stars

RE:RE:What Hunter Syndrome Could Be Worth:

"reached therapeutic levels in the CNS and significantly decreased the number of lysosomal storage vacuoles in the cytoplasm of brain cells." Read more at http://www.stockhouse.com/news/press-releases...read more
4.5 stars

RE:What Hunter Syndrome Could Be Worth:

That's ~$300 million in Canadian dollars for Armagen's preclinical deal with Shire and I can't see any data in knockout mice. Given Transcend is 6.4 times more effective at crossing the blood-brain...read more
5 stars

RE:What Hunter Syndrome Could Be Worth:

Yes...that's what a deal could be worth however what could a straight up purchase of lsd be worth aswell as Hunter syndrome. ...why not sell lsd ...take say 400million for it....take that money and...read more
1.5 stars

RE:RE:RE:RE:RE:News Alert

I also always wonder about that idea not to release good news on Friday. As Jim Rockford here posted, no man is stronger than the markets - so there is no such thing as getting special permanent...read more
5 stars

What Hunter Syndrome Could Be Worth:

ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome ArmaGen to Receive up to Approximately $225 Million Including Initial...read more